FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer

References

• Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27:5931 - 7; http://dx.doi.org/10.1200/JCO.2009.22.4295; PMID: 19884549
   PubMed Web of Science ®Google Scholar
• Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005; 65:6063 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-05-0404; PMID: 16024606
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27:5924 - 30; http://dx.doi.org/10.1200/JCO.2008.21.6796; PMID: 19884556
   PubMed Web of Science ®Google Scholar
• Halliwell B. A super way to kill cancer cells?. Nat Med 2000; 6:1105 - 6; http://dx.doi.org/10.1038/80436; PMID: 11017139
   PubMed Web of Science ®Google Scholar
• von Roretz C, Lian XJ, Macri AM, Punjani N, Clair E, Drouin O, et al. Apoptotic-induced cleavage shifts HuR from being a promoter of survival to an activator of caspase-mediated apoptosis. Cell Death Differ 2013; 20:154 - 68; http://dx.doi.org/10.1038/cdd.2012.111; PMID: 22955946
   PubMed Web of Science ®Google Scholar
• Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 2001; 8:705 - 11; http://dx.doi.org/10.1016/S1097-2765(01)00320-3; PMID: 11583631
   PubMed Web of Science ®Google Scholar
• Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2:647 - 56; http://dx.doi.org/10.1038/nrc883; PMID: 12209154
   PubMed Web of Science ®Google Scholar
• Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNFfamily death receptors. Oncogene 2003; 22:8628 - 33; http://dx.doi.org/10.1038/sj.onc.1207232; PMID: 14634624
   PubMed Web of Science ®Google Scholar
• Roy S, Nicholson DW. Cross-talk in cell death signaling. J Exp Med 2000; 192:21 - 6; http://dx.doi.org/10.1084/jem.192.8.F21; PMID: 11034597
   PubMed Web of Science ®Google Scholar
• Kandasamy K, Srinivasula SM, Alnemri ES, Thompson CB, Korsmeyer SJ, Bryant JL, et al. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res 2003; 63:1712 - 21; PMID: 12670926
   PubMed Web of Science ®Google Scholar
• Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687 - 90; http://dx.doi.org/10.1074/jbc.271.22.12687; PMID: 8663110
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Bálint B, de Boer RH, van Meerbeeck JP, Wierzbicki R, De Souza P, et al. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2013; 8:329 - 37; PMID: 23370314
   PubMed Web of Science ®Google Scholar
• Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ Jr., Rocha-Lima CM, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 2012; 23:2834 - 42; http://dx.doi.org/10.1093/annonc/mds142; PMID: 22700995
   PubMed Web of Science ®Google Scholar
• Demetri GD, Le Cesne A, Chawla SP, Brodowicz T, Maki RG, Bach BA, et al. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. Eur J Cancer 2012; 48:547 - 63; http://dx.doi.org/10.1016/j.ejca.2011.12.008; PMID: 22240283
   PubMed Web of Science ®Google Scholar
• Lenk H, Tanneberger S, Müller U, Ebert J, Shiga T. Phase II clinical trial of high-dose recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1989; 24:391 - 2; http://dx.doi.org/10.1007/BF00257449; PMID: 2791193
   PubMed Web of Science ®Google Scholar
• Smith TL, Lee JJ, Kantarjian HM, Legha SS, Raber MN. Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. J Clin Oncol 1996; 14:287 - 95; PMID: 8558210
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155 - 62; http://dx.doi.org/10.1172/JCI6926; PMID: 10411544
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Poulaki V, Mitsiades CS, Koutras DA, Chrousos GP. Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases. Trends Endocrinol Metab 2001; 12:384 - 90; http://dx.doi.org/10.1016/S1043-2760(01)00441-6; PMID: 11595539
   PubMed Web of Science ®Google Scholar
• Zhan C, Wei X, Qian J, Feng L, Zhu J, Lu W. Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo. J Control Release 2012; 160:630 - 6; http://dx.doi.org/10.1016/j.jconrel.2012.02.022; PMID: 22410115
   PubMed Web of Science ®Google Scholar
• Kelly MM, Hoel BD, Voelkel-Johnson C. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther 2002; 1:520 - 7; http://dx.doi.org/10.4161/cbt.1.5.169; PMID: 12496481
   PubMed Web of Science ®Google Scholar
• Ashley DM, Riffkin CD, Lovric MM, Mikeska T, Dobrovic A, Maxwell JA, et al. In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. Br J Cancer 2008; 99:294 - 304; http://dx.doi.org/10.1038/sj.bjc.6604459; PMID: 18594532
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Poulaki V, Mitsiades C, Tsokos M. Ewing’s sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res 2001; 61:2704 - 12; PMID: 11289151
   PubMed Web of Science ®Google Scholar
• Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277:818 - 21; http://dx.doi.org/10.1126/science.277.5327.818; PMID: 9242611
   PubMed Web of Science ®Google Scholar